ErVimmune

Executive Summary

ErVimmune is a French biotechnology company pioneering next-generation cancer immunotherapies by targeting non-conventional tumor antigens derived from human endogenous retroviruses (HERVs). Founded in 2019 and based in Paris, the company leverages a proprietary AI-driven discovery platform to identify shared epitopes across patients and cancer types, aiming to transform immunologically 'cold' tumors with high unmet medical need into responsive ones. ErVimmune's approach includes both vaccines and T cell-based therapies, differentiating it from conventional immunotherapies that focus on neoantigens or overexpressed proteins. By targeting HERV-derived antigens, which are stably expressed and immunogenic, the company seeks to address a broad patient population across multiple indications. Although still in preclinical stages with no disclosed funding or valuation, ErVimmune's innovative angle on activating the immune system against cancer positions it as a potential player in the immuno-oncology space. Its success hinges on the ability of its AI platform to efficiently predict immunogenic HERV epitopes and the translation of these discoveries into viable clinical candidates. The company's focus on cold tumors represents a significant opportunity given the current limitations of checkpoint inhibitors and CAR-T therapies in these settings.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Vaccine Candidate40% success
• Q2 2027Partnership with Major Pharma for AI Platform30% success
• Q3 2026Preclinical In Vivo Data Presentation at Major Conference60% success